Respiratory infections are a major cause of global mortality and morbidity. In recent years, an increased incidence of multidrug-resistant (MDR) Gram-negative bacteria (GNB) has been described. Microorganisms such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae or Acinetobacter baumannii have been identified as causative pathogens of different respiratory tract infections. Several studies have detected MDR-GNB in patients with communityacquired and nosocomial pneumonia. Furthermore, MDR-GNB have also been isolated in patients with chronic obstructive pulmonary disease and bronchiectasis having acute or chronic bronchial infection. Prevalence varies depending on the geographical area but MDR-GNB has been reported in the Asia-Pacific region, Europe and the United States, reaching rates of 70% in hospital-acquired infection. The presence of MDR-GNB has been related to poor clinical outcomes, including increased mortality, although data regarding this relationship are limited. This is probably linked to inappropriate selection of empiric antibiotic treatment; this poses a threat of widespread resistance. GNB antibiotic resistance and the absence of new antibiotics are a major concern given limited treatment options; an aspect that deserves future research. We review current literature, highlight prevalence of MDR-GNB in different respiratory infections and explore their impact on clinical outcomes.
INTRODUCTION
Respiratory infections are some of the most common causes of human illness and the leading cause of death from infectious diseases worldwide. 1 Communityacquired pneumonia (CAP), nosocomial pneumonia and acute and chronic bronchial infections in patients with chronic obstructive pulmonary disease (COPD) and bronchiectasis are the most common respiratory infections and are related to an elevated morbidity and mortality.
A large proportion of Gram-negative bacteria (GNB) are the causative pathogens of these lower respiratory tract infections. Several studies have reported an increased rate of GNB as causal agents in recent years, especially in hospital-acquired infections and also in patients coming from the community. 2 The presence of GNB is related to poor clinical outcomes, probably due to its ability to become resistant to the most common antibiotics used.
Antibiotic resistance is a global public threat because of its effect on health care, including higher costs, prolonged hospitalizations and increased mortality. Bacterial antibiotic resistance causes more than 25 000 deaths per year in Europe, and costs more than $1.5 billion per year in healthcare expenses and productivity loses. 3 In the United States (US), about 2 million people acquire serious infections caused by bacteria resistant to at least one recommended antibiotic. 4 The emergence of GNB antibiotic resistance and the lack of novel antibiotics in the development pipeline represent one of the biggest respiratory threats in the recent years. In this study, we aimed to review data from the last 10 years regarding the prevalence of resistant GNB in respiratory infections and their impact on clinical outcomes.
MDR-GNB IN RESPIRATORY INFECTIONS
Multidrug-resistant (MDR) GNB are an important cause of bacterial resistance. The most frequent MDR or potentially drug-resistant GNB isolated in respiratory infections are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, Stenotrophomonas maltophilia and other Enterobacteriaceae sp. 5 Other GNB responsible for different respiratory infections such as Haemophilus influenzae are not the issue of concern in this review, because they are not frequently resistant to the most common antibiotics used to treat respiratory infections.
P. aeruginosa is a versatile microorganism that is the leading cause of opportunistic human infections. 6 Treatment failure due to the development of resistance is indeed a frequent outcome in patients suffering from P. aeruginosa infections. Due to its ability to induce changes in different single genes, it generates mutants that are resistant to clinical concentrations of all antimicrobial agents used for therapy. 7 Another important feature is its capacity to produce biofilms to evade antibiotic effect. Biofilms are communities of bacteria attached to a surface, expressing different properties from planktonic cells as an increased resistance to antimicrobial therapy and host defence. 8 P. aeruginosa is responsible for severe nosocomial infections, especially in the intensive care units (ICU). 9, 10 However, it has also been described in patients with pneumonia coming from the community 11 and it is well recognized as a major cause of chronic respiratory infections in patients with bronchiectasis and COPD. 12, 13 E. coli, K. pneumoniae and other Enterobacteriaceae sp. are responsible for different respiratory infections acquired in the hospital setting, although some studies have also reported the presence of these GNB in nonnosocomial infections. 2 They have the property of being resistant to different antibiotic treatments. Specifically, they are able to produce extended-spectrum β-lactamases (ESBL), including carbapenemases that can hydrolyse most β-lactams, including the carbapenems. Carbapenem-producing Enterobacteriaceae (CPE) are related to high morbidity and mortality 14, 15 because in many cases carbapenems are the last-line antibiotics.
A. baumannii is an opportunistic pathogen that is frequently involved in outbreaks of infection, occurring mostly in the ICU. A. baumannii have been described as a cause of respiratory infections following hospitalization in patients with severe illness. MDR isolates of A. baumannii have been reported increasingly during the last years, especially against carbapenems, and have been related to poor clinical outcomes. 16 Different definitions for MDR bacteria have being used in the literature. The European Centre for Disease Prevention and Control (ECDC) and the Centres for Disease Control and Prevention (CDC) joined in 2011 to standardize the terminology used to describe acquired resistant profiles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), P. aeruginosa and Acinetobacter spp., all related to healthcare-associated infections. In the definitions proposed, non-susceptibility refers to either, resistant or intermediate result from in vitro antimicrobial susceptibility test. 17 MDR was defined as non-susceptibility to at least one agent in three or more antimicrobial categories. In addition, extensively drug resistant (XDR) was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories and pandrug resistance (PDR) as nonsusceptibility to all agents in all antimicrobial categories (Fig. 1) .
MDR-GNB IN CAP
CAP is the most common lower respiratory tract infection and the leading cause of death to infection worldwide. 18, 19 CAP is typically caused by pathogens such as Streptococcus pneumoniae, H. influenzae and atypical pathogens that are sensitive to most of the first-line antibiotics. 20 However, over the last years, new pathogens that were usually confined within the hospital setting, including GNB such as P. aeruginosa, K. pneumoniae or E. coli, have emerged in the community causing pneumonia in immunocompetent patients. In 2005, the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines introduced the healthcare-associated pneumonia (HCAP) as a new term that identified healthcare-related risk factors associated with these potentially MDR pathogens in patients coming from the community with pneumonia. These risk factors included prior hospitalization, nursing home resident, home infusion therapy, chronic dialysis within 30 days, home wound care and/or family member with MDR. Broad-spectrum antibiotic therapy similar to hospital-acquired pneumonia (HAP) was recommended for these patients. 21 However, over the last years, several studies have evaluated the issues related to MDR pathogens and HCAP, [22] [23] [24] and a systematic review and meta-analysis concluded that HCAP does not accurately identify MDR pathogens. 25 Furthermore, a recent review evaluated the different MDR risks factors and prediction scores developed in the last years, and suggested that a different approach focusing on risk factors for specific MDR pathogens would be needed. 26 The prevalence of GNB (both in general and specifically MDR) in CAP has been evaluated in several studies (Table 1) . Prospective European studies have reported an overall GNB prevalence lower than 5% of all-CAP aetiologies. [28] [29] [30] However, some recent studies conducted in Asian countries reported higher prevalences, ranging from around 10% to 20% in China and Japan 22, 27, [33] [34] [35] 37 up to 30% in Taiwan. 36 The most frequent GNB isolated were P. aeruginosa, 28, 33, 37 K. pneumoniae 22, 27, 31, 34, 36 and E. coli. 29, 32 The presence of HCAP, 28, 30, [32] [33] [34] 39 chronic respiratory disease 28, 29, 33 and aspiration 30, 39 were the risk factors more strongly related to the presence of GNB CAP.
Some of these studies that have evaluated the prevalence of drug-resistant pathogens among GNB reported different rates of incidence depending on the country. Li et al. reported that 62% of E. coli, 40% of P. aeruginosa and 36% of K. pneumoniae were MDR in China. 31 In a prospective study conducted in Italy with 935 hospitalized CAP patients, P. aeruginosa was isolated as MDR in 58% and E. coli was ESBL in 33% of the patients. 32 The presence of ESBL was also reported in a Japanese study, with an incidence of 18% among E. coli and only 2% among K. pneumoniae. 34 In a Chinese study, among 450 bacterial hospitalized CAP patients, the presence of ESBL reached 10% of all GNB. 33 Finally, a recent prospective study including 68 cases of CAP due to P. aeruginosa in Spain showed that 32% of P. aeruginosa was MDR. Prior antibiotic treatment was present in 58% of the MDR cases, and was the only risk factor associated with CAP resulting from MDR P. aeruginosa.
38
The presence of GNB has been related to poor clinical outcomes in CAP, probably due to an inappropriate antibiotic treatment. 26 Several studies have reported increased mortality among patients suffering CAP due to GNB compared with those with another aetiologies. 27, 29, 32, [37] [38] [39] However, the presence of MDR-GNB and its impact on clinical outcomes have been poorly evaluated. Prina et al. demonstrated that the presence of P. aeruginosa, Enterobacter ESBL and methicillin-resistant S. aureus (MRSA) were independently associated with increased risk of 30-day mortality. 37 However, Cilloniz et al. 38 found no differences among ICU admission, criteria of acute respiratory distress syndrome (ARDS) and 30-day mortality among patients with P. aeruginosa CAP with and without MDR.
MDR-GNB IN NOSOCOMIAL PNEUMONIA
Nosocomial pneumonia is a leading cause of infections in hospital setting, and includes HAP and ventilatorassociated pneumonia (VAP). In the recent ATS/IDSA HAP/VAP guidelines, the term HAP is defined as an episode of pneumonia not associated with mechanical ventilation and not incubated at the time of hospital admission (>48 h after admission). Otherwise, VAP is defined as a pneumonia occurring >48 h after endotracheal intubation. 40 There are a lot of studies using these two terms in different ways. Some of them use HAP referring to any pneumonia developing in the hospital, and other exclude VAP from HAP designation. However, both HAP and VAP are associated with considerable morbidity, prolonged hospitalization, increased costs and mortality, and may be caused by MDR-GNB.
Several recent studies have reported an elevated prevalence of GNB in nosocomial pneumonia, ranging from 25% in Poland 41 up to 85% in Europe and in the US 42, 43 (Table 2 ). Different microorganisms have been described as the most frequent ones. Chien et al. 44 described a prevalence of 47% for P. aeruginosa (30% of them were MDR) and 30% for A. baumannii (94% of them were MDR) in patients with VAP in a prospective study conducted in Taiwan. Behnia et al. 43 described a higher prevalence of S. maltophilia (31%) in a retrospective study of patients diagnosed with nosocomial and VAP admitted in an ICU in the US. In this study, the prevalence of P. aeruginosa was 22% and 19% for A. baumannii. In a randomized controlled trial that included 740 patients with VAP in the US and Canada, 45 the authors described an overall GNB prevalence of 33%, and K. pneumoniae was the most common one (24%). Other studies described a higher isolation of Enterobacteriaceae among patients with nosocomial pneumonia. Guzek et al. 41 evaluated retrospectively more than 2000 patients with VAP and positive bacterial cultures in Poland and showed a high prevalence of Enterobacteriaceae (42%), with an incidence of ESBL of 26%. In addition, Koulenti et al. 42 described a prevalence of 51% for Enterobacteriaceae among 827 patients with HAP and VAP in a multicentre prospective study in Europe and Di Pasquale 47 showed that Enterobacteriaceae was responsible for 47% of ICU-acquired pneumonia in Spain.
Other studies have evaluated the specific impact of MDR P. aeruginosa among nosocomial pneumonia. In an international multicentre retrospective study that included 750 patients with P. aeruginosa nosocomial pneumonia among 12 hospitals in five countries (US, France, Germany, Italy and Spain), the authors described a prevalence of MDR of 30% among P. aeruginosa nosocomial pneumonia. 48 Independent predictors for MDR included decreased age, diabetes mellitus and ICU admission. Another study evaluated 91 cases of VAP due to P. aeruginosa in Spain, 46 and described a prevalence of MDR of 66%. Interestingly, among MDR strains, 70% of them were XDR. Patients with MDR-P. aeruginosa VAP had a higher rate of immunosuppressive therapy and diabetes compared with those patients with non-MDR P. aeruginosa VAP.
Nosocomial pneumonia due to MDR-GNB has been linked with poor clinical outcomes. Chien et al. 44 reported that MDR pathogens were independently associated with increased 6-month mortality and Parker et al. showed an increased risk of 28-day and hospital mortality. 45 Likewise, other studies described that MDR P. aeruginosa was independently associated with a higher in-hospital mortality, 48 ICU length of stay, days of mechanical ventilation and received less empirical appropriate antibiotic therapy compared with those with susceptible P. aeruginosa in patients with VAP. 46 On the other hand, some studies did not found significant differences in clinical outcomes related to the presence of MDR pathogens in HAP and VAP. Di Pasquale et al. 47 found no differences in clinical and inflammatory characteristics, severity of illness and mortality among patients with and without MDR pathogens. Behnia et al. 43 described no strong relationship between MDR strains and death or need for surgical intervention or between nosocomial pneumonia or VAP. Further studies are needed to better understand the impact on outcomes of MDR pathogens in VAP, especially due to their elevated prevalence.
MDR-GNB IN COPD
COPD is a common chronic respiratory disease characterized by a progressive persistent airflow limitation and is an important cause of morbidity and mortality. 49, 50 During clinical stability, potentially pathogenic microorganisms (PPM) can be isolated in 30-50% of COPD patients. 51, 52 This airway colonization has been associated with higher inflammation 53, 54 and more frequent exacerbations, 55 playing a negative role in the clinical course of the illness. The most frequent PPM in the airways of COPD patients are H. influenzae, S. pneumoniae and Moraxella catarrhalis, although MDR-GNB, especially P. aeruginosa, can also be isolated in these patients, especially in the most severe ones.
Few studies have evaluated the impact of MDR-GNB in clinically stable COPD patients (Table 3) . Engler et al. 58 analysed the incidence of chronic P. aeruginosa colonization in a subgroup of 112 patients with COPD and a previous positive respiratory sample for P. aeruginosa. During the follow-up, authors detected that 41% of these patients have chronic P. aeruginosa colonization. The 58% of Pseudomonas aeruginosa (PA) isolations were sensitive to all the antibiotics tested, whereas 11% were resistant to three or more groups of antibiotics (MDR). In addition, Gallego et al. 60 evaluated the prevalence of P. aeruginosa among COPD patients who attended a Respiratory Day Unit for an acute exacerbation that did not require hospitalization, and followed them up for 1 year. P. aeruginosa was isolated in 35% of the patients, and chronic colonization was determined only in 12%. Regarding antibiotic resistance, 47% of PA isolations were sensitive to all tested antibiotics and 27% were MDR. By contrast, Sibila et al. 62 only determined an incidence of 2% of GNB in a prospective study including 45 severe stable COPD patients, where bronchial colonization was determined using bronchoscopic samples. In this study, where patients with bronchiectasis were excluded, P. aeruginosa was not isolated in any respiratory sample.
Acute exacerbations of COPD (AECOPD) contribute to the progression of the disease and are the most important cause of hospital admission and mortality. Infection is the most frequent cause of exacerbation (70%), mainly due to bacteria. 64, 65 Bacterial pathogens isolated in AECOPD can vary depending on the severity of illness, with GNB, specially P. aeruginosa, being more common in exacerbations of severe COPD patients. 50, 66, 67 Table 3 shows recent studies evaluating the role of GNB during AECOPD in the last years. Lin et al. 56 in a retrospective study in Taiwan described an incidence higher than 50% of GNB as causative microorganisms, K. pneumoniae being the most common GNB isolated (36%), followed by P. aeruginosa (31%). The isolation of P. aeruginosa was associated with prolonged admission, was a predictor of respiratory failure requiring mechanical ventilation and was related to higher mortality. However, the prevalence of MDR P. aeruginosa was very low (2%). Another study conducted in China 31 studied the differences in clinical outcomes and antibiotic susceptibilities between patients with CAP and AECOPD, and found higher rates of P. aeruginosa and A. baumannii in COPD. In this study, the most common GNB isolated in AECOPD was again K. pneumoniae (53%). Prevalence of MDR was very high, reaching 45% in P. aeruginosa and 37% and 64% in ESBL K. pneumoniae and E. coli, respectively. Finally, Ma et al. 61 reported a GNB prevalence of 30% among 318 AECOPD patients in China, whereas K. pneumoniae was again the most common one.
Other studies have described the prevalence of GNB during AECOPD and the rate of MDR in Spain. GarciaVidal et al., 57 in a prospective study that include 188 patients, found an overall prevalence of GNB of 21%, with P. aeruginosa being the most common one (77%) with an elevated rate of MDR (87%). The BODE (body mass index (BMI), airflow obstruction, dyspnoea and exercise capacity) index, 68 admissions in the previous year and previous isolation were the risk factors associated with P. aeruginosa isolation. Domenech et al. 59 showed a GNB prevalence of 32% among 224 severe COPD patients with acute exacerbation, with P. aeruginosa being the most prevalent one (74%). Our group undertook a prospective study to evaluate the resistance patterns and clinical outcomes in 54 patients admitted with an AECOPD due to P. aeruginosa. 63 In this study, prevalence of MDR was 53%. Regarding outcomes evaluated, patients with sensitive bacteria had a higher rate of short-term mortality, whereas patients with MDR had increased P. aeruginosa persistence in the sputum after a proper antibiotic treatment, suggesting that important differences in the virulence characteristics of sensitive and MDR isolates exist in this population, although further studies are needed to confirm these findings.
Colonization and infection remain controversial terms in these patients, and further studies are required to differentiate where organisms are acutely acquired compared with chronic biofilm-associated infections. The role of airway microbiome in these patients may be crucial to better understand this complex relationship among acute and chronic infections in COPD. 69 
MDR-GNB IN BRONCHIECTASIS
Non-cystic fibrosis (CF) bronchiectasis (hereafter referred to as bronchiectasis) is a chronic airway disease characterized by abnormal dilatation of large airways, bronchi and bronchioles. 70 Failure of innate antimicrobial defences leads to chronic bacterial colonization of the airways in these patients, causing an increased inflammatory response that can further increase airway inflammation and airway structural damage, leading to the well-described 'vicious cycle' of bronchiectasis. 71 Patients with bronchiectasis may be colonized with organisms that are upper airway commensals such as S. pneumoniae or H. influenzae. However, a significant proportion of patients are colonized with potentially drug-resistant GNB, especially P. aeruginosa, which is related to poor outcomes (Table 4) .
King et al., 72 in a prospective study in Australia, described that 15% of the patients were colonized with GNB. Among them, P. aeruginosa was the most common one (85%) and was resistant to antibiotics in 27% of the cases. During an average period of 6 years of follow-up, resistance to antibiotics increases up to 50%, especially to gentamicin. The presence of P. aeruginosa was related to more hospital admissions, exacerbations, radiological severity and decline in lung function tests. Furthermore, patients with resistant bacteria were more likely to have been hospitalized and have had a greater number of exacerbations compared with those with sensitive bacteria.
Several other studies have evaluated the impact of P. aeruginosa in clinically stable patients with bronchiectasis, [72] [73] [74] [75] [76] [77] [78] [79] [80] although incidence and impact on outcomes of MDR bacteria were not evaluated. In these observational studies, incidence of P. aeruginosa varied from 10% to 20%, 72, 76, 77, 80 around 30% 75, 78 and up to 50% 74 and in most of the cases was related to worse clinical outcomes. Finch et al. 81 performed an analysis of the impact of P. aeruginosa colonization on prognosis of bronchiectasis patients using data derived from 21 observational cohort studies, including 3683 patients. In this study, the authors showed that P. aeruginosa was associated with a highly significant and consistent increase in all markers of disease severity, including mortality, hospital admission and exacerbations, as well as worse quality of life, decreased lung function and increased radiological severity. Furthermore, two multidimensional severity scores have been developed in bronchiectasis in recent years: the Bronchiectasis Severity Index (BSI) 77, 78 and the FACED score. 82 Both scores included P. aeruginosa colonization as an item of severity, increasing risk of hospital admission and mortality. However, the presence of MDR P. aeruginosa and its impact on outcomes were not evaluated.
Although P. aeruginosa was the most common GNB detected in all the studies, other potentially MDR-GNB was also described in clinically stable patients with bronchiectasis. Enterobacteriaceae was found in the sputum of around 30-40% of the colonized patients in two prospective multicentre European studies, 77, 79 E. coli was detected in around 20% of the colonized patients in Australia, 72 Spain and Scotland, 78 and S. maltophilia was grown in the sputum of around 40% of the colonized patients in Belgium. 76 Few studies have evaluated the impact of GNB during acute exacerbations in patients with bronchiectasis. In patients admitted with bronchiectasis and CAP, the incidence of P. aeruginosa was 15% and 9% for Enterobacteriaceae (higher than in CAP patients without bronchiectasis). 83 In a cohort of 60 hospitalized exacerbations of bronchiectasis without pneumonia, P. aeruginosa was again the most common microorganism isolated in sputum culture in around 30% of the patients. 84 Patients with P. aeruginosa had lower forced expiratory volume in 1 s (FEV 1 ), a higher number of exacerbations in the previous year and a higher rate of chronic P. aeruginosa infection in comparison to those without P. aeruginosa. No data regarding the incidence and impact on outcomes of drug-resistance pathogens were available in this population. Furthermore, as it happened in COPD patients, the limitations among chronic colonization and acute infection due to MDR-GNB in bronchiectasis are not clear, and this is an important topic that deserves further research.
CONCLUSIONS
GNB are causative microorganisms of several respiratory infections, including pneumonia and bronchial infections in patients with chronic respiratory conditions such as COPD and bronchiectasis. Studies performed in the last 10 years have documented GNB prevalence higher than 50% in patients with nosocomial pneumonia, around 20% in CAP and ranging from 10% to 50% in COPD and bronchiectasis patients. Prevalence varies depending on geographic areas, with a consistently higher GNB prevalence in the Asian region in patients with pneumonia (both CAP and VAP) and COPD. Regarding microorganisms, K. pneumoniae (in Asian studies) and P. aeruginosa (in European studies) and are the most common GNB isolated.
Only around half of the studies published in the last years have evaluated specific resistance to antibiotics in GNB, with differing prevalence between countries and continents. Again, MDR P. aeruginosa seems to be more prevalent in Europe (especially in COPD patients in Spain) and ESBL pathogens (mostly K. pneumoniae and E. coli) are more prevalent in the Asia-Pacific region.
Most of the studies have related the presence of GNB with worse clinical outcomes, including higher mortality in CAP, HAP, VAP, AECOPD and bronchiectasis. However, most of the studies considered all GNB as potentially drug-resistant pathogens, and only few studies have evaluated the impact of real MDR (resistant to three or more antibiotic families) pathogens.
In summary, the presence of MDR-GNB together with the lack of development of new antibiotics represents a major threat in respiratory medicine for the coming years. Appropriate selection of initial empiric treatment is crucial in patients with respiratory infections, and may be very difficult (or even impossible) in these patients. Further studies are urgently needed in order to better understand specific risk factors for MDR-GNB and their real impact on clinical outcomes. 
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